DTB Podcast

February 2019: The past, present and future of inhaled corticosteroids for COPD

In February's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the use of inhaled corticosteroids in the management of COPD (https://dtb.bmj.com/content/57/2/18). The editors also consider subclinical hypothyroidism in pregnancy (https://dtb.bmj.com/content/57/2/22) and discuss Gilbert’s syndrome (https://dtb.bmj.com/content/57/2/27).
Read the full issue: https://dtb.bmj.com/content/57/2

January 2019: Challenging the supremacy of intravenous antibiotics

In January's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss whether intravenous antibiotics are always needed. The editors also consider the challenge of stopping antipsychotic drug treatment in people with intellectual disability and review a case of angioedema of the small bowel caused by lisinopril.
Read the issue: dtb.bmj.com/content/57/1.

December 2018: Information on medicines for patients

In December's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the conditional authorisation process for medicines and the need for clearer labelling of medicines that have been through this approval processes. The editors also consider common sources of information on medicines for patients and review a case of interstitial lung disease associated with adalimumab.
Read the issue: https://dtb.bmj.com/content/56/12.

November 2018: Travelling with medicines

In November's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss a recent study that compared a coordinated, multi-professional, multi-faceted primary care approach to managing people with multiple long-term conditions with usual general practice care. The editors also consider problems faced by patients who need to travel overseas with controlled drugs and review a case of splenic rupture associated with rivaroxaban.
Read the November issue: https://dtb.bmj.com/content/56/11.

October 2018: atrial fibrillation, opioids for chronic pain and over-the-counter sildenafil

In October's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the place of population screening for atrial fibrillation and the need for more evidence to support a change in national policy (https://dtb.bmj.com/content/56/10/112).
The editors also consider problems associated with long-term opioid use in the management of chronic pain (https://dtb.bmj.com/content/56/10/118). Please watch the video about Michael's moving story on this subject at dtb.bmj.com.
The launch of slidenafil as an over-the-counter pharmacy medicine (https://dtb.bmj.com/content/56/10/123) is also discussed.
Read the latest from the reinvented Drug and Therapeutics Bulletin here: dtb.bmj.com.

Here’s your New DTB!

In September's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) highlight some of the changes to DTB that have taken place this month and discuss the background and rationale to these changes. Read this month's editorial: https://dtb.bmj.com/content/56/9/98.
The editors also consider the place for monitored dosage systems (https://dtb.bmj.com/content/56/9/102) and discuss the evidence for using labetalol as a first-line treatment option for hypertension in pregnancy (https://dtb.bmj.com/content/56/9/107).
Meet the new DTB here: https://dtb.bmj.com/content/56/9.

August 2018: what’s your position on giving birth?

In the August's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the results of an awarding research paper that assessed the impact of spending the second stage of labour either in a recumbent or upright position.
Read the editorial: https://dtb.bmj.com/content/56/8/85.
The editors also consider nutritional support in primary care (https://dtb.bmj.com/content/56/8/90) and discuss new licensing pathways that provide faster access to medicines (https://dtb.bmj.com/content/56/8/93).

July 2018: managing herbal-drug interactions

In July’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the risk of drug interactions with herbal medicines.
Read the editorial: https://dtb.bmj.com/content/56/7/73.
The editors also review the evidence for ocrelizumab for relapsing MS and early primary progressive MS (https://dtb.bmj.com/content/56/7/80), and discuss the role of metformin in people with type 1 diabetes (https://dtb.bmj.com/content/56/7/78).

June 2018: Antidepressants - there is no news

In the June’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss whether a recently published large meta-analysis on the effectiveness of antidepressants tells us anything new. Read the editorial here: dtb.bmj.com/content/56/6/61.
The editors also review the evidence for the combination analgesic of tramadol/dexketoprofen (dtb.bmj.com/content/56/6/66), and question the dose of paracetamol for older people (dtb.bmj.com/content/56/6/69).

May 2018: Does pulmonary rehabilitation need more PR?

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the evidence for pulmonary rehabilitation for COPD and highlight the need for more publicity for its benefits. Read the editorial here: http://dtb.bmj.com/content/56/5/49.
The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile infection in adults who are at high risk of recurrence (http://dtb.bmj.com/content/56/5/57).